Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasms, Unknown Primary 1Neoplasms 1NSCLC 1Head and Neck Neoplasms 1First-line Advanced NSCLC Patients 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Carboplatin 13Paclitaxel 8Bevacizumab 7Gemcitabine 4130-nm albumin-bound paclitaxel 4liposomal doxorubicin 3relacorilant 2pembrolizumab 2nintedanib 2epothilone B 2Drug Therapy 2Albumin-Bound Paclitaxel 2volociximab 1tremelimumab 1phenoxodiol 1oregovomab 1olaparib 1lanreotide 1farletuzumab 1enzastaurin 1durvalumab 1cc-486 1catumaxomab 1atezolizumab 1Trastuzumab 1Trabectedin 1Topotecan 1Saline Solution 1Oxaliplatin 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Peritoneal Neoplasms × CP protocol × Clear all
NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡